Helmut Burtscher
Cancer Research · 2009
A researcher in the Science corpus: 1 paper; trusts 0 researchers and is trusted by 0 researchers here, as inferred from the citation graph.
Papers from Helmut Burtscher's perspective
Ordered by how strongly the researchers Helmut Burtscher trusts endorse each paper. Same corpus, a different order for every researcher.
- Inhibitory Fc receptors modulate in vivo cytoxicity against tumor targets (Nature Medicine)
- Targeting ligand-activated ErbB2 signaling inhibits breast and prostate tumor growth. (Cancer Cell)
- Insights into ErbB signaling from the structure of the ErbB2-pertuzumab complex. (Cancer Cell)
- Untangling the ErbB signalling network (Nature reviews. Molecular cell biology)
- The HER-2-Targeting Antibodies Trastuzumab and Pertuzumab Synergistically Inhibit the Survival of Breast Cancer Cells (Cancer Research)
- Theoretical Basis, Experimental Design, and Computerized Simulation of Synergism and Antagonism in Drug Combination Studies
- Trastuzumab (herceptin), a humanized anti-Her2 receptor monoclonal antibody, inhibits basal and activated Her2 ectodomain cleavage in breast cancer cells. (Cancer Research)
- A Unified Approach to Simultaneous Rank Test Procedures in the Unbalanced One-way Layout
- Structure of the extracellular region of HER2 alone and in complex with the Herceptin Fab (Nature)
- Ligand-independent HER2/HER3/PI3K complex is disrupted by trastuzumab and is effectively inhibited by the PI3K inhibitor GDC-0941. (Cancer Cell)